Global Medical Aesthetic Products Market Research Report Information by Product (Botulinum Toxin, Dermal Fillers), by Application, by Gender, by End User, by Region Forecast Till 2032

Description

List of Tables

Global Medical Aesthetic Products Market Research Report Information by Product (Botulinum Toxin (Botox), Dermal Fillers), by Application (Hair Removal, Skin Resurfacing, Facial Rejuvenation, Liposuction, Facelifts, Skin Grafting, Wrinkle Reduction, Others), by Gender (Male, Female), by End User (Hospitals & Dermatological Clinics, Medical Spas, Beauty Clinics), by Region (North America, Europe, Asia-Pacific, Rest of the World) Forecast Till 2032

Market Overview

The market size of medical aesthetic products was estimated to be USD 8,971.27 million in 2023. It is anticipated that the Global Medical Aesthetic Products industry will expand at a compound annual growth rate (CAGR) of 10.8% from USD 9,702.34 Million in 2024 to USD 22,032.40 Million by 2032. This expansion is anticipated to transpire during the forecast period of 2024 to 2032.

The Medical Aesthetic Products Market is being stimulated by the increasing acceptance and introduction of botox and dermal fillers, as well as the increasing popularity of minimally invasive cosmetic procedures.

The Medical Aesthetic Products Market is expanding significantly due to the increasing prevalence of minimally invasive cosmetic procedures. Botox and dermal fillers have gained popularity among consumers who are seeking effective solutions to enhance their appearance without the protracted recovery period typically associated with surgical options. The immediate results and minimal discomfort of these procedures make them appealing to a diverse spectrum of individuals, including younger individuals who are pursuing preventative treatments. The convenience and safety profile of these minimally invasive options, in conjunction with advancements in techniques and formulations, have made them highly appealing. The overall expansion of the market is anticipated to be driven by the ongoing increase in awareness of the benefits through social media and influencer endorsements, which is expected to contribute to the demand for these cosmetic interventions.

Market segment insights

Based on product, the Medical Aesthetic Products Market has been divided into botulinum toxin (Botox) and dermal fillers. A further division of botulinum toxin (Botox) is Type A and Type B. Dermal fillers are further classified as hyaluronic acid, calcium hydroxylapatite, poly-l-lactic acid, polymethyl-methacrylate microspheres (PMMA), and polyalkylimide.

The Market has been categorized into the following categories based on application: hair removal, skin resurfacing, facial rejuvenation, liposuction, facelifts, skin grafting, wrinkle reduction, and others.

The Medical Aesthetic Products Market has been divided into male and female segments according to gender.

The market has been divided into three categories based on the end user: hospitals and dermatological clinics, medical retreats, and cosmetic clinics.

Regional Perspectives

According to region, the Medical Aesthetic Products Market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America's market share was the highest in 2023 and is anticipated to reach USD 8,594.84 million by 2032. Nevertheless, it is anticipated that the Asia-Pacific region will experience the most substantial compound annual growth rate (CAGR) of 12.46% during the forecast period. The Europe Medical Aesthetic Products Market was valued at USD 2,545.23 million in 2023 and is expected to experience a compound annual growth rate (CAGR) of 11.62% during the forecast period. The additional segments of Europe include the United Kingdom, Italy, France, Spain, and Germany. The Asia-Pacific Medical Aesthetic Products Market was valued at USD 1,631.78 million in 2023 and is expected to experience a compound annual growth rate (CAGR) of 12.46% during the forecast period. Subregions of the Asia-Pacific region include China, India, Japan, South Korea, Australia, New Zealand, and the Rest of Asia-Pacific.

Major Players

The Medical Aesthetic Products Market is primarily participated in by Suneva Medical, Abbvie, Inc., Bioxis Pharmaceuticals, Merz Pharma, Galderma, Sinclair, Medytox, Teoxane, and Dr. Korman.

Product Code: MRFR/HC/41750-CR

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING POPULARITY OF MINIMALLY INVASIVE COSMETIC PROCEDURES
- 4.2.2 RISING APPROVAL AND LAUNCH FOR DERMAL FILLERS AND BOTOX
4.3 RESTRAINTS
- 4.3.1 SIDE EFFECTS ASSOCIATED WITH DERMAL FILLERS AND BOTOX
- 4.3.2 FOOD AND DRUG ADMINISTRATION (FDA) WARNING LETTER ASSOCIATED WITH THE DERMAL FILLERS
- 4.3.3 FAKE AND COUNTERFEIT VERSION OF BOTOX FILLERS
4.4 OPPORTUNITY
- 4.4.1 GROWING GERIATRIC POPULATION

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON MEDICAL AESTHETIC PRODUCTS MARKET
5.3 CONSUMER PREFERENCE
5.4 REGULATORY LANDSCAPE
- 5.4.1 NORTH AMERICA
- 5.4.2 EUROPE
- 5.4.3 ASIA-PACIFIC
- 5.4.4 MIDDLE EAST & AFRICA
5.5 MARKET TRENDS IN THE MEDICAL AESTHETIC PRODUCTS MARKET
5.6 PRICING ANALYSIS
5.7 LIST OF TRADERS AND DISTRIBUTORS REGION/COUNTRY
5.8 LIST OF MANUFACTURERS
5.9 PROCEDURE ANALYSIS ON REGIONAL LEVEL (2019-2023)

6 MEDICAL AESTHETIC PRODUCTS MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 BOTULINUM TOXIN (BOTOX)
- 6.2.1 TYPE A
- 6.2.2 TYPE B
6.3 DERMAL FILLERS
- 6.3.1 HYALURONIC ACID
- 6.3.2 CALCIUM HYDROXYLAPATITE
- 6.3.3 POLY-L-LACTIC ACID
- 6.3.4 POLYMETHYL-METHACRYLATE MICROSPHERES (PMMA)
- 6.3.5 POLYALKYLIMIDE
- 6.3.6 OTHERS

7 MEDICAL AESTHETIC PRODUCTS MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 HAIR REMOVAL
7.3 SKIN RESURFACING
7.4 FACIAL REJUVENATION
7.5 LIPOSUCTION
7.6 FACELIFTS
7.7 SKIN GRAFTING
7.8 WRINKLE REDUCTION
7.9 OTHERS

8 MEDICAL AESTHETIC PRODUCTS MARKET, BY GENDER

8.1 OVERVIEW
8.2 MALE
8.3 FEMALE

9 MEDICAL AESTHETIC PRODUCTS MARKET, BY END USER

9.1 OVERVIEW
9.2 HOSPITALS & DERMATOLOGICAL CLINICS
9.3 MEDICAL SPAS
9.4 BEAUTY CLINICS

10 MEDICAL AESTHETIC PRODUCTS MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
- 10.4.1 CHINA
- 10.4.2 INDIA
- 10.4.3 JAPAN
- 10.4.4 SOUTH KOREA
- 10.4.5 AUSTRALIA
- 10.4.6 NEW ZEALAND
- 10.4.7 REST OF ASIA PACIFIC
10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA
  - 10.5.3.1 ARGENTINA
  - 10.5.3.2 BRAZIL
  - 10.5.3.3 COLOMBIA
  - 10.5.3.4 REST OF LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, DERMAL FILLERS,
11.3 MARKET SHARE ANALYSIS, BOTULINUM TOXIN (BOTOX),
11.4 COMPETITOR DASHBOARD
11.5 PUBLIC PLAYERS STOCK SUMMARY
11.6 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.1.1 PRODUCT LAUNCH
- 11.1.2 PRODUCT APPROVAL
- 11.1.3 AGREEMENT
- 11.1.4 EXPANSION

12 COMPANY PROFILES

12.1 REVANCE THERAPEUTICS
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 ABBVIE, INC.
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
12.3 SUNEVA MEDICAL
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 BIOXIS PHARMACEUTICALS
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGIES
12.5 MERZ PHARMA
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
12.6 GALDERMA
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
12.7 SINCLAIR
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
12.8 MEDYTOX
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 KEY STRATEGIES
12.9 TEOXANE
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 DR. KORMAN
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

13 DATA CITATIONS